+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07668869

Comparing Tumor Treating Fields With and Without FET-PET-Guided Stereotactic Radiosurgery for Adults With Recurrent IDH-Wildtype Glioblastoma

Led by Prof. Franciszek Lukaszczyk Memorial Oncology Center · Updated on 2026-06-25

92

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether adding FET-PET-guided stereotactic radiosurgery SRS to Tumor Treating Fields TTFields therapy improves survival in adults with recurrent IDH-wildtype glioblastoma. This brain tumor has limited treatment options and a poor outlook. The study is a prospective randomized trial comparing combined treatment with TTFields alone to determine if survival at one year improves. Participants are randomly assigned to receive either TTFields plus FET-PET-guided SRS or TTFields alone. TTFields treatment is delivered continuously through scalp-placed transducer arrays for four months. For those in the combined group, stereotactic radiosurgery is performed within 14 days after starting TTFields, targeting tumor areas based on MRI and FET-PET imaging to improve treatment precision. During the study, participants undergo assessments including survival monitoring up to one year and other outcomes such as progression-free survival, response rates, and treatment-related side effects. Researchers collect imaging and molecular data to evaluate treatment effects and safety. The total participation lasts several months with follow-up for survival and tumor progression.

CONDITIONS

Brief Title

TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)

Research Team

A

Agnieszka Rydzewska, Study Coordinator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here